Duration
12 months
Cost
Free to Patients
Phase
Phase III
Closes
Sep 2025
Testing whether CBD added to existing seizure medications reduces seizure frequency in adults with drug-resistant focal epilepsy.
Patient Advocacy Endorsed
This trial has been reviewed and endorsed by Epilepsy Foundation. PAG endorsement means patient advocates have evaluated the trial design, risk-benefit profile, and patient-friendliness of this study.
Only 34 spots remaining
Apply soon to secure your place.
Trial Summary